Lung Cancer News and Research

Latest Lung Cancer News and Research

Statins could be effective against metastatic small cell lung cancer

In a recent study, researchers at Cancer Treatment Centers of America at Western Regional Medical Center (Western), in collaboration with international colleagues, found that statins could be an effective therapeutic against metastatic small cell lung cancer (SCLC).

7 Jan 2016

NIH-funded clinical study examines new method for sparing healthy lung tissue during radiotherapy

A newly NIH funded clinical trial (NCT02528942) by University of Colorado Cancer Center investigators and collaborators at Beaumont Health in Michigan and the University of Texas Medical Branch is evaluating a new method for pinpointing and sparing healthy lung tissue during lung cancer radiotherapy.

7 Jan 2016

Pediatric oncologists devise new treatments for neuroblastoma

Pediatric oncologists from The Children's Hospital of Philadelphia have reported their latest results in devising new treatments for stubbornly deadly forms of the childhood cancer neuroblastoma.

7 Jan 2016

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has announced the initiation of a multinational randomized Phase 3 open-label study of its lead product candidate, Pexa-Vec (formerly JX-594), in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC).

5 Jan 2016

Xcovery to present data from X-396 Phase l/ll trial in patients with ALK+ NSCLC at AACR-IASLC conference

Xcovery, a developer of targeted therapeutics for ALK+ non-small cell lung cancer (NSCLC) is scheduled to present January 6th, 2016 at the fourth annual AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic, at the Hard Rock Hotel, in San Diego, CA.

5 Jan 2016

NCCLC patients with KRAS-related gene mutations may benefit from triple therapy

Although the most common type of lung cancer - non-small cell lung cancer (NSCLC) - has recently seen major treatment advances in some genetic subtypes, other subtypes continue to evade effective treatment. (New therapies exist for NCCLC patients whose cancers harbor mutations in the ALK or EGFR genes, for example.)

4 Jan 2016

FDA approves non-alcoholic Docetaxel Injection

Teikoku Pharma USA, Inc. announced today that the U.S. Food and Drug Administration has approved Docetaxel Injection, Non-Alcohol Formula ("Docetaxel Injection") for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

29 Dec 2015

Personalized respiratory-motion system enables more precise lung cancer imaging

Lung cancer patients know that precise medical imaging can help a surgeon eradicate tumors and preserve healthy tissue.

24 Dec 2015

IASLC lauds FDA approval of alectinib for lung cancer treatment

The International Association for the Study of Lung Cancer (IASLC) is once again gratified to see the approval of a new second-generation lung cancer treatment that can help many patients in their battle against the disease.

24 Dec 2015

Study: Low-dose CT screening can reduce lung cancer mortality by 20% in high-risk population

A national study involving 53,000 patients and 11 institutions (including Wake Forest Baptist) compared CT screens with chest X-rays and found that the scanning reduced lung cancer mortality by 20 percent in this high-risk population.

23 Dec 2015

TIGER-X study reviews efficacy of rociletinib therapy in patients with EGFR mutant-positive NSCLC

Oncology & Hematology Review, the peer-reviewed journal, has published a review highlighting recent data around rociletinib, an investigational therapy in patients with previously treated EGFR mutant-positive non-small cell lung cancer.

23 Dec 2015

Biocept agrees $15 million common stock purchase deal with Aspire

Biocept, Inc., a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection, monitoring and treatment of cancer, announces a $15 million common stock purchase agreement with Aspire Capital Fund, LLC, a Chicago-based institutional investor.

22 Dec 2015

Researchers reveal inherited genetic errors across 12 cancer types

Researchers long have known that some portion of the risk of developing cancer is hereditary and that inherited genetic errors are very important in some tumors but much less so in others.

22 Dec 2015

Study shows more patients with advanced NSCLC may benefit from pembrolizumab

More patients with advanced non-small-cell lung cancer (NSCLC) could benefit from pembrolizumab, says Professor Roy Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, presenting promising results from the pivotal phase 2/3 KEYNOTE-010 trial at the first ESMO Asia Congress in Singapore), in conjunction with a publication in The Lancet.

22 Dec 2015

Immunotherapy more effective than chemotherapy in treating patients with advanced lung cancer

A new study has found immunotherapy to be more effective than chemotherapy in treating most previously treated patients with advanced lung cancer, and demonstrated effectiveness in a wider population of people than previously known to benefit from the therapy.

22 Dec 2015

Patients with EGFR-mutated lung cancer benefit more from afatinib as first-line treatment

Patients with EGFR-activating mutations in advanced lung cancer seem to benefit more from afatinib than gefitinib as first-line treatment, researchers report at the first ESMO Asia 2015 Congress in Singapore.

21 Dec 2015

Halozyme Therapeutics, Lilly sign global collaboration and license agreement

Halozyme Therapeutics, Inc. today announced a global collaboration and license agreement with Eli Lilly and Company to develop and commercialize products combining proprietary Lilly compounds with Halozyme's ENHANZE platform.

21 Dec 2015

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

Mirati Therapeutics, Inc. today announced that the Phase 2 clinical trial of glesatinib (MGCD265) has commenced. The Company also announced that "glesatinib" is the proposed generic name for MGCD265.

21 Dec 2015

Adaptimmune begins Phase I/II study of affinity enhanced T-cell therapy targeting MAGE-A10 in NSCLC patients

Adaptimmune Therapeutics plc, a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has initiated a Phase I/II study of its affinity enhanced T-cell therapy targeting the MAGE-A10 cancer antigen in patients with locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC), the most prevalent type of lung cancer representing approximately 85 percent of lung cancers.

21 Dec 2015

Family members of CUP patients at higher risk of developing CUP themselves

Cancer usually begins in one location and then spreads, but in 3 percent to 5 percent of cancer patients, the tissue where a cancer begins is unknown. In these individuals a cancer diagnosis is made because it has metastasized to other sites. Patients with these so-called "cancers of unknown primary," or CUP, have a very poor prognosis, with a median survival of three months.

18 Dec 2015

Lung Cancer News and Research

Latest Lung Cancer News and Research

Statins could be effective against metastatic small cell lung cancer

NIH-funded clinical study examines new method for sparing healthy lung tissue during radiotherapy

Pediatric oncologists devise new treatments for neuroblastoma

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

Xcovery to present data from X-396 Phase l/ll trial in patients with ALK+ NSCLC at AACR-IASLC conference

NCCLC patients with KRAS-related gene mutations may benefit from triple therapy

FDA approves non-alcoholic Docetaxel Injection

Personalized respiratory-motion system enables more precise lung cancer imaging

IASLC lauds FDA approval of alectinib for lung cancer treatment

Study: Low-dose CT screening can reduce lung cancer mortality by 20% in high-risk population

TIGER-X study reviews efficacy of rociletinib therapy in patients with EGFR mutant-positive NSCLC

Biocept agrees $15 million common stock purchase deal with Aspire

Researchers reveal inherited genetic errors across 12 cancer types

Study shows more patients with advanced NSCLC may benefit from pembrolizumab

Immunotherapy more effective than chemotherapy in treating patients with advanced lung cancer

Patients with EGFR-mutated lung cancer benefit more from afatinib as first-line treatment

Halozyme Therapeutics, Lilly sign global collaboration and license agreement

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

Adaptimmune begins Phase I/II study of affinity enhanced T-cell therapy targeting MAGE-A10 in NSCLC patients

Family members of CUP patients at higher risk of developing CUP themselves

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in